Dihydroresveratrol

Dihydroresveratrol

SCHEMBL716856

Oc1ccc(CCc2cc(O)cc(O)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 1.00
ESR1 P03372 4/20 0.74
ESR2 Q92731 2/20 0.74
TYR P14679 1/20 0.59
CA2 P00918 1/20 0.56
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP2C19 P33261 2/20 0.54
ADRA2A P08913 2/20 0.54
SLC6A2 P23975 2/20 0.54
HTR1A P08908 1/20 0.54
HTR3A P46098 1/20 0.54
BACE1 P56817 1/20 0.54
TAAR1 Q96RJ0 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
SLC28A3 Q9HAS3 2/20 0.54
CALM1 P0DP23 1/20 0.53
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24193843 0.90 LTA4H (0.82) LTA4HESR1ESR2TYRCA2
SCHEMBL69344 0.86 ESR1 (1.00) LTA4HESR1ESR2TYRCA2
SCHEMBL3873458 0.86 ESR1 (1.00) LTA4HESR1ESR2TYRCA2
SCHEMBL10149325 0.86 LTA4H (0.74) LTA4HESR1ESR2TYRBACE1
SCHEMBL18328929 0.83 LTA4H (0.71) LTA4HESR1ESR2TYRTAAR1
SCHEMBL11674563 0.83 LTA4H (0.71) LTA4HESR1ESR2TYRTAAR1
Dihydropinosylvin SCHEMBL501070 0.82 LTA4H (0.70) LTA4HESR1ESR2TYRCALM1
SCHEMBL716875 0.80 ESR1 (0.67) LTA4HESR1ESR2TYRCA2
SCHEMBL29862145 0.80 CALM1 (0.86) LTA4HESR1ESR2CALM1PTPN1
SCHEMBL16568144 0.80 CALM1 (0.86) LTA4HESR1ESR2CALM1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078269-A1 POLYMERIC COMPOSITIONS WITH STILBENE-BASED PROCESSING AIDS Cambium Biomaterials, Inc. (US) 2026-03-19 US claimed
EP-4687856-A2 GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING JDS Therapeutics, LLC (US) 2026-02-11 EP claimed
WO-2025227265-A1 METHODS FOR CONCENTRATING POLYPHENOLIC COMPOUNDS CANURTA INC. (CA) 2025-11-06 WO claimed
EP-4601749-A1 ORAL COMPOSITIONS AND RELATED METHODS Colgate-Palmolive Company (US) 2025-08-20 EP claimed
CN-116162017-B Preparation method of trans-resveratrol 西安久启生物科技有限公司 2025-02-11 CN claimed
WO-2024229159-A2 GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING JDS THERAPEUTICS, LLC (US) 2024-11-07 WO claimed
US-20240366525-A1 GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING JDS THERAPEUTICS, LLC 2024-11-07 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
CN-118286188-A Application of dihydroresveratrol in preparation of subtype adenovirus inhibitor 广州医科大学附属妇女儿童医疗中心 2024-07-05 CN claimed
WO-2024112884-A1 BIOSYNTHESIS OF DIHYDROCHALCONES AND DIHYDROSTILBENOIDS CONAGEN INC. (US) 2024-05-30 WO claimed
WO-2016193504-A1 BIOSYNTHESIS OF PHENYLPROPANOID AND DIHYDROPHENYLPROPANOID DERIVATIVES EVOLVA SA (CH) 2016-12-08 WO claimed
US-20160311976-A1 PHTHALONITRILES DERIVED FROM POLYPHENOLS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2016-10-27 US claimed
US-8853343-B1 Thermoset compositions from plant polyphenols THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2014-10-07 US claimed
US-8728453-B2 Combinatorial polymeric compositions for drug delivery INNOVOTECH, LLC (US) 2014-05-20 US claimed
US-20140018437-A1 TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-01-16 US claimed
US-20140017341-A1 COMPOSITION AND METHOD FOR TREATING FAT TISSUES AND INFLAMMATORY PROCESSES GOURLAOUEN BRIGITTE (FR) 2014-01-16 US claimed
EP-2629744-A1 PRODUCT FOR TREATING CELLULITE, SKIN AGEING AND FOR PREVENTING INFLAMMATORY PROCESSES Gourlaouen, Brigitte (FR) 2013-08-28 EP claimed
US-20120220749-A1 COMBINATIORIAL POLYMERIC COMPOSITIONS FOR DRUG DELIVERY INNOVOTECH, LLC 2012-08-30 US claimed
WO-2012052685-A1 PRODUCT FOR TREATING CELLULITE, SKIN AGEING AND FOR PREVENTING INFLAMMATORY PROCESSES GOURLAOUEN BRIGITTE (FR) 2012-04-26 WO claimed
EP-2049091-B1 CASEIN COMPLEXES DSM IP ASSETS BV (NL) 2010-12-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311976-A1 PHTHALONITRILES DERIVED FROM POLYPHENOLS NR3C2, MECP2, EBP LTA4H 3677/4885ESR1 351/4885ESR2 450/4885
US-20260078269-A1 POLYMERIC COMPOSITIONS WITH STILBENE-BASED PROCESSING AIDS SMCHD1, TERB1, NLRP3 LTA4H 872/4885ESR1 154/4885ESR2 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.